货号：I3134

储存条件：粉末-20°C可保存3年；液体-80°C可保存12月。

产品描述

Toll like receptors (TLR) is a family with ten members that are known to be important for provoking the innate immunity and establishing adaptive immunity. The imiquimod is TLR7 and 8 agonist with EC50 value of 1.5 μM on TLR7. It is effective in treating a variety of primary skin cancers and cutaneous metastases of some malignancies.
Imiquimod reduced cell numbers on the DFT1 and DFT2 cells lines in a concentration dependent manner as measured by the WST-8 proliferation assay after incubating with 7.5 - 60 μg/ml of imiquimod for 24 hours. When the cells were incubated with 60 μg/ml of imiquimod for 72 hours, most of cells entered apoptotic pathways and complete apoptosis for all the cells occurred at 120 hours as measured by annexin V and PI staining .
When 30 mg/mouse of imiquimod was applied for seven consecutive days on the back skin of late telogen C57BL/6 mice one day after hair removal, the number of CD45 positive cells increased compared with control group as measure by flow cytometry. The level of IL-6, Cxcl-1, TNF-a, IL23p19 and IL-17a examined by quantitative real-time reverse transcription PCR were induced in the imiquimod treatment group.

 作用机制

Imiquimod could preferentially bind to TLR7 and to a lesser extent, TLR8.

 产品信息